None listed
Conditions
Interventions
None listed
Sponsors
Korea Cancer Center Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with histologically confirmed CD20-positive relapsed or refractory B-cell non-Hodgkin’s lymphoma Patients who received 131I-rituximab radioimmunotherapy (RIT) at our institution between 2005 and 2020 Patients who underwent 18F-FDG PET/CT scans at all three time points: before RIT (PET1), 5 days after RIT (PET2), and 1 month after RIT (PET3) Patients with a history of prior rituximab treatment were also eligible
Exclusion criteria
Exclusion criteria: Patients without complete 18F-FDG PET/CT data at all three time points (PET1, PET2, and PET3) Patients with hypermetabolic lymph node lesions near the right carotid artery on any of the PET/CT scans, which could interfere with SUV (standardized uptake value) measurements in the target vessel
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Target-to-Background Ratio (TBR) representing the degree of inflammation in the carotid atherosclerotic plaque. TBR is calculated as the ratio of the maximum standardized uptake value (SUVmax) of the right carotid artery to the mean SUV of the inferior vena cava on PET/CT. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of post-treatment changes in TBR (TBR2 and TBR3) between two patient groups, stratified by baseline TBR1 (above vs. below the median). This evaluates the differential anti-inflammatory effect of RIT depending on baseline plaque inflammation. | — |
Countries
Korea, Republic of
Contacts
Public ContactByung hyun Byun
Korea Cancer Center Hospital
Outcome results
None listed